In addition, aripiprazole was less favorable for akathisia compared with second-generation D 2R antagonists, in particular olanzapine and quetiapine, and less favorable for discontinuation due to inefficacy than risperidone. Specifically, aripiprazole was more favorable than paliperidone for triglyceride levels and more favorable than risperidone and olanzapine, but less favorable than ziprasidone, for weight gain. However, aripiprazole was more favorable than pooled D 2R antagonists for depressive symptoms, prolactin levels, and triglyceride levels. Aripiprazole was the only identified D 2R partial agonist, and was not significantly different from pooled D 2R antagonists for overall symptom reduction or all-cause discontinuation. Fourteen RCTs, involving 2494 patients, were included in the meta-analysis. The aim of this meta-analysis was to directly compare D 2R partial agonists with D 2R antagonists for efficacy and tolerability, using randomized controlled trials (RCTs) that involved participants diagnosed with first-episode psychosis, schizophrenia, or related psychotic disorders with a duration of illness ≤5 years. However, there is limited guidance in the scientific literature on how best to choose between dopamine D 2 receptor (D 2R) partial agonists and D 2R antagonists in early stages of schizophrenia. Early intervention is essential for favorable long-term outcomes in schizophrenia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |